Fig. 1 · Structure

Documents & Downloads

Fludarabine

Cat. No. A10396 CAS 21679-14-1

STAT inhibitor

Fludarabine or fludarabine phosphate (Fludara) is a chemotherapy drug used in the treatment of hematological malignancies (cancers of blood cells such as leukemias and lymphomas) .Fludarabine inhibits DNA synthesis by interfering with ribonucleotide reductase and DNA polymerase. It is active against both dividing and resting cells.

In Stock

Publications for Fludarabine

1 publication citing this product

  1. Irene Dell'Anno, .et al. , Invest New Drugs, 2020, Dec 9 PMID: 33300108

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
STAT1 (Vascular smooth muscle cells)

Cellular Effect

Cell Line Activity Value Description Reference
A549 IC50 47.44 μM Cytotoxicity against human A549 cells after 72 hrs by MTT assay [PMID: 20605656]
CCRF-CEM IC50 19.49 μM Cytotoxicity against human CEM cells after 72 hrs by MTT assay [PMID: 20605656]
HCT-116 IC50 6.6 μM Cytotoxicity against human HCT116 cells after 72 hrs by SRB assay [PMID: 25462277]
HCT-116 IC50 8 μM Antiproliferative activity against human HCT116 cells after 72 hrs by SRB assay [PMID: 29326016]
HeLa EC50 16 μM Antitumor activity against human HeLa cells assessed as cell viability by MTT assay [PMID: 24673739]
HepG2 IC50 20 μM Antiproliferative activity against human HepG2 cells after 72 hrs by SRB assay [PMID: 29326016]
Huh-7 IC50 30 μM Antiproliferative activity against human HuH7 cells after 72 hrs by SRB assay [PMID: 29326016]
Huh-7 IC50 60.1 μM Cytotoxicity against human HuH7 cells after 72 hrs by SRB assay [PMID: 25462277]
JVM-2 EC50 10.4 μM Antitumor activity against human JVM2 cells assessed as cell viability after 48 hrs by FACS analysis [PMID: 24673739]
K562 IC50 0.26 μM Cytotoxicity against human paclitaxel-resistant K562 cells after 72 hrs by MTT assay [PMID: 20605656]
K562 IC50 0.6 μg/mL Inhibitory concentration required against human chronic myelogenous leukemic K-562 cell line after 48h, using [3H]thymidine incorporation assay [PMID: 12617912]
K562 IC50 0.6 μg/mL Inhibitory concentration required against human chronic myelogenous leukemic K-562 cell line after 5h, using [3H]thymidine incorporation assay [PMID: 12617912]
K562 IC50 267 μM Cytotoxicity against human K562 cells after 72 hrs by MTT assay [PMID: 20605656]
Mahlavu IC50 10 μM Antiproliferative activity against human Mahlavu cells after 72 hrs by SRB assay [PMID: 29326016]
MCF7 IC50 15 μM Antiproliferative activity against human MCF7 cells after 72 hrs by SRB assay [PMID: 29326016]
PBMC IC50 1.9 μM Cytotoxicity against patient PBMC after 48 hrs by CellTitre-Blue assay [PMID: 25562417]
PBMC IC50 10 μM Cytotoxicity against patient PBMC after 48 hrs by CellTitre-Blue assay in presenc of mouse M210B4 cells [PMID: 25562417]
PBMC IC50 14 μM Cytotoxicity against healthy human PBMC after 48 hrs by CellTitre-Blue assay [PMID: 25562417]
T47D IC50 46.2 μM Cytotoxicity against human T47D cells after 72 hrs by SRB assay [PMID: 25462277]

19 records · Scroll to view more

In Vitro Studies

Fludarabine reduced the MTT proliferation-associated signal in five mesothelioma cell lines at 1 μM. In the same time-course assay framework, the non-malignant MeT-5A, LP-9 and HMC7 models showed no reported proliferation reduction under the represented conditions. Responses were measured over 24–72 h and are assay- and model-dependent. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Fludarabine response in malignant and non-malignant mesothelial cell models

Cell-based study · Mero-14, Mero-25, IST-Mes2, NCI-H28 and MSTO-211H mesothelioma cells; non-malignant MeT-5A, LP-9 and HMC7 mesothelial models [1]

Fludarabine reduced the MTT proliferation-associated signal in the five malignant lines. The non-malignant models showed no reported proliferation reduction under the represented conditions. MTT is a metabolic surrogate, not a direct cell count or clinical safety test.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Proliferation-associated MTT signal versus vehicleQualitative time-course response Reduced in all five MPM lines with 1 μM F-araA; no reported reduction in MeT-5A at the tested 1 and 10 μM conditions.[1]
MTT signal in additional non-malignant mesothelial modelsQualitative time-course response LP-9 and HMC7 proliferation was not affected by 1 μM F-araA in this assay.[1]

Literature-Reported Treatment Conditions

Treatment concentration
1 and 10 μM for Figure 2A; 1 μM for Figure 3A–B
Exposure duration
24, 48 and 72 h after treatment; pretreatment baseline shown
Method
Cell treatment 24 h after seeding; MTT time course
Co-treatment
Single-agent fludarabine; risedronic acid panels not selected.
Reported limits
Main text does not identify the specific solvent or final vehicle fraction for these MTT panels; matched vehicle controls were used. No IC50 calculated here.
Methods and source locations

Compound reported in the paper: Fludarabine (F-araA); Compound label in the paper: Fludarabine (F-araA)

Compound-level cellular evidence; does not establish analytical identity, potency or performance of an A10396 lot.

Figure 2A; Figure 3A–B; MTT assay; Chemicals; Statistical analysis

Proliferation-associated MTT signal versus vehicle: MTT optical density; Figure 2: mean ± SEM, three independent experiments, each in triplicate. No exact curve values extracted. — Figure 2A and caption; Results: Short-term proliferation and colony formation assays

MTT signal in additional non-malignant mesothelial models: Figure 3A–B: mean ± SEM of two independent experiments, each in duplicate; vehicle controls. — Figure 3A–B and caption; Results: Short-term proliferation and colony formation assays

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 21679-14-1
Applications STAT inhibitor
Formula C10H12FN5O4
Molecular Weight 285.2
Synonyms F-ara-A; NSC 118218; Fludara
SMILES
C1=NC2=C(N=C(N=C2N1[C@H]3[C@H]([C@@H]([C@H](O3)CO)O)O)F)N

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 52 mg/mL (182.3 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
28 mg/mL
Vehicle
30% propylene glycol, 5% Tween 80, 65% D5W

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Irene Dell’Anno, Sarah A. Martin, Marcella Barbarino, et al. Drug-repositioning screening identified fludarabine and risedronic acid as potential therapeutic compounds for malignant pleural mesothelioma Investigational new drugs (2021). PMID: 33300108 DOI: 10.1007/s10637-020-01040-y Source material

Publications

1 publication citing this product

  1. Irene Dell'Anno, .et al. , Invest New Drugs, 2020, Dec 9 PMID: 33300108

Added to your cart

View Cart Checkout
Loading...